Skip to main content

New Cerebrospinal Fluid Research to Uncover Mechanisms Driving Neurological and Psychiatric Diseases - Volume II

32kviews
Editorial12 December 2023
Editorial: New cerebrospinal fluid research to uncover mechanisms driving neurological and psychiatric diseases, volume II

Cerebrospinal fluid (CSF) examination is a key procedure in diagnosis of autoimmune, infectious and malignant diseases of the nervous system. In the last years, the relevance of CSF analysis in neurodegenerative and neuropsychiatric disorders further increased. Since the discovery of autoimmune encephalitis (AE) driven by autoantibodies directed to the N-methyl-D-aspartate (NMDA) receptor further autoantibodies against neuronal structures such as the contactin-associated proteinlike 2 (CASPR2) were identified, and the important role of CSF in the diagnosis and monitoring of AE arose (McCracken et al., 2017, Durr et al., 2021). Additionally, CSF analysis has gained renewed importance in diagnosing multiple sclerosis (MS), particularly with the introduction of the 2017 McDonald criteria (Thompson et al., 2018). These criteria allow the use of CSF oligoclonal bands to demonstrate dissemination in time, facilitating earlier diagnosis and treatment initiation. Despite the growing body of knowledge regarding CSF diagnostics, there remains significant scope to enhance our understanding and improve the diagnostic accuracy for a variety of neurological and psychiatric disorders, including the identification of new biomarkers. This Research Topic covers various topics related to CSF analyses in both neurological and psychiatric diseases.In the first paper, Berger and colleagues focused on evaluating treatment responses in AE patients, distinguishing between seronegative and seropositive groups. They analysed data from 150 AE patients treated at their university hospital between 2010 and 2020. Among these, 49 patients did not show specific AE antibodies (seronegative), whereas 57 were identified with known AE antibodies (seropositive). The majority of these patients, approximately 80%, received at least one form of immunotherapy. The authors utilized the modified ranking scale to assess the clinical response to these treatments. A key observation from this study was the comparable effectiveness of immunotherapy in both seropositive and seronegative patients, with no marked differences in treatment outcomes between the two groups. This finding suggests the possibility of unidentified antibodies being present in many of the seronegative AE cases. It also provides valuable insights into managing AE patients, proposing that immunomodulatory therapies could be beneficial for AE treatment regardless of antibody status.The polyspecific intrathecal immune response (PSIIR), also known as the MRZ reaction (M = measles, R = rubella, Z = zoster), is known to occur in the majority of patients with MS and is considered to have a high diagnostic specificity for this disease (Jarius et al., 2017). In this context, two studies in the collection have explored its diagnostic utility in MS and other conditions. Vlad and colleagues conducted a study focusing on the differential diagnosis of neurosarcoidosis and MS, a challenging task due to the similarities between these conditions. They retrospectively analyzed CSF samples from 27 neurosarcoidosis patients and compared them with samples from 138 patients with relapsing-remitting MS (RRMS). Notable differences were observed in the CSF profiles of these two groups. Based on their findings, they concluded that the combination of CSF white cell counts >30/µl, absence of CSF-specific oligoclonal bands, and the absence of positive MRZ reaction was able to distinguish between the diseases with a sensitivity and specificity of >92%. In another of the contributing papers, Brauchle and colleagues examined the frequency of PSIIR in older patients (over 50 years) with chronic autoimmune inflammatory neurological diseases other than MS. They analysed PSIIR test results from 415 patients and found that 76 of them tested positive for PSIIR. Of these, 25 (33%) did not meet the diagnostic criteria for MS or its related spectrum of diseases. Long-term followup data was available for 13 patients, all of whom exhibited a progressive course of disease. Based on these observations, Brauchle and colleagues concluded that PSIIR might serve as a marker for previously unrecognized chronic neurological autoimmune conditions, suggesting a need for further research to better understand this phenomenon.Subarachnoid hemorrhage (SAH), a potentially life-threatening condition, requires quick diagnosis and treatment. Weller and colleagues conducted a study exploring the prognostic value CSF metabolite analysis in SAH cases. They focused particularly on the arginine/ornithine ratio in the CSF, investigating its ability to predict cerebral vasospasms and overall clinical outcomes in patients with SAH. Their analysis included 38 SAH patients, and their findings indicated that the arginine/ornithine ratio in the CSF serves as an independent predictor of the clinical outcome. Based on this, they proposed that the arginine/ornithine ratio could be integrated into clinical practice, enhancing the existing prognostic models for SAH.Finally, Endres and colleagues detailed an interesting case report of a woman who developed obsessive-compulsive disorder (OCD) post-partum. Their investigation revealed the presence of novel anti-nucleoli autoantibodies in the patient's CSF. These autoantibodies were detected in cerebellar Purkinje cells and cortical neurons, as demonstrated through tissue-based assays using mouse brain slices. This finding suggest an autoimmune link, offering new insights into the origins of such neuropsychiatric conditions. This second volume of "New Cerebrospinal Fluid Research to Uncover Mechanisms Driving Neurological and Psychiatric Diseases -Volume II" in the "Frontiers of Neurology" demonstrates the important role of CSF analysis in diagnosing and predicting neurological and psychiatric diseases. It further emphasises the need for further research in this field and shows how CSF analysis can directly influence appropriate patient care.

1,252 views

Therapy response in seronegative versus seropositive autoimmune encephalitis
Background Autoimmune encephalitis (AE) might be seropositive or seronegative, depending on whether antibodies targeting well-characterized neuronal antigens can be detected or not. Since data on treatment efficacy in seronegative cases, are scarce, the main rationale of this study was to evaluate immunotherapy response in seronegative AE in comparison to seropositive cases. Methods An electronic database search retrospectively identified 150 AE patients, treated in our tertiary care university hospital between 2010 and 2020 with an AE. Therapy response was measured using both general impression and the modified Rankin Scale (mRS). Results Seventy-four AE patients (49.3%) were seronegative and 76 (50.7%) seropositive. These cases were followed up for a mean of 15.3 (standard deviation, SD, 24.9) and 24.3 months (SD 28.1), respectively. Both groups were largely similar on the basis of numerous clinical and paraclinical findings including cerebrospinal fluid, electroencephalography, magnetic resonance imaging, and 18-F-fluor-desoxy-glucose-positron-emmission-tomography pathologies. The majority of patients (80.4%) received at least one immunotherapy, which were glucocorticoids in most cases (76.4%). Therapy response on general impression was high with 49 (92.5%) of treated seronegative, and 57 (86.4%) of treated seropositive AE cases showing improvement following immunotherapies and not significantly different between both groups. Notably, the proportion of patients with a favorable neurological deficit (mRS 0-2) was twice as high during long-term follow-up as compared to baseline in both groups. Conclusions Since both, patients with seronegative and seropositive AE, substantially benefitted from immunotherapies, these should be considered in AE patients irrespective of their antibody results.

8,054 views

20 citations

Background: Neurosarcodosis is one of the most frequent differential diagnoses of multiple sclerosis (MS) and requires central nervous system (CNS) biopsy to establish definite diagnosis according to the latest consensus diagnostic criteria. We here analyzed diagnostic values of basic cerebrospinal fluid (CSF) parameters to distinguish neurosarcoidosis from MS without CNS biopsy. Methods: We retrospectively assessed clinical, radiological and laboratory data of 27 patients with neurosarcoidosis treated at our center and compared following CSF parameters with those of 138 patients with relapsing-remitting MS: CSF white cell count (WCC), CSF/serum albumin quotient (Qalb), intrathecal production of immunoglobulins including oligoclonal bands (OCB), MRZ reaction, defined as a polyspecific intrathecal production of IgG reactive against ≥2 of 3 the viruses measles (M), rubella (R), and zoster (Z) virus, and CSF lactate levels. Additional inflammatory biomarkers in serum and/or CSF such as neopterin, soluble interleukin-2 receptor (sIL-2R) and C-reactive protein (CRP) were assessed. Results: There was no significant difference in the frequency of CSF pleocytosis, but a CSF WCC > 30/l was more frequent in patients with neurosarcoidosis. Compared to MS, patients with neurosarcoidosis showed more frequently an increased Qalb and CSF lactate levels as well as increased serum and CSF levels of sIL-2R, but a lower frequency of intrathecal IgG synthesis and positive MRZ reaction. Positive likelihood ratio (PLR) of single CSF parameters indicating neurosarcoidosis was highest, if (a) CSF WCC was >30/l (PLR 7.2), (b) Qalb was >10×10−3 (PLR 66.4), (c) CSF-specific OCB were absent (PLR 11.5), (d) CSF lactate was elevated (PLR 23.0) or (e) sIL-2R was elevated (PLR>8.0). The combination of (a) one of three following basic CSF parameters, i.e. (a.1.) CSF WCC >30/ul, or (a.2.) QAlb >10×10−3, or (a.3.) absence of CSF-specific OCB, and (b) absence of positive MRZ reaction showed the best diagnostic accuracy (sensitivity and specificity each >92%; PLR 12.8 and NLR 0.08). Conclusion: Combined evaluation of basic CSF parameters and MRZ reaction is powerful in differentiating neurosarcoidosis from MS, with moderate to severe pleocytosis and QAlb elevation and absence of intrathecal IgG synthesis as useful rule-in parameters and positive MRZ reaction as a rule-out parameter for neurosarcoidosis.

6,859 views

16 citations

CASE REPORT
30 August 2022
Case Report: Possible autoimmune obsessive-compulsive disorder with postpartum onset
Dominique Endres, 9 more and Ludger Tebartz van Elst

4,769 views

8 citations